OSE Immunotherapeutics SA (EPA: OSE)

OSE Immunotherapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	25.86	18.67	25.62	33.58	29.37	25.84
Short-Term Investments	49.89	-	-	-	-	-
Cash & Short-Term Investments	75.75	18.67	25.62	33.58	29.37	25.84
Cash Growth	404.37%	-27.12%	-23.70%	14.34%	13.64%	107.83%
Accounts Receivable	4.98	0.98	0.4	0.77	1.07	0.75
Other Receivables	0.96	6.61	5.98	5.18	5.85	3.71
Receivables	5.94	7.59	6.39	5.95	6.92	4.46
Prepaid Expenses	2.45	2.75	3.45	2.96	2.5	1.79
Other Current Assets	1.65	1.47	1.74	1.72	1.05	0.98
Total Current Assets	85.79	30.48	37.2	44.21	39.83	33.06
Property, Plant & Equipment	3.65	4.07	4.98	5.44	3.8	2.7
Other Intangible Assets	0.13	0.14	0.17	0.15	-	-
Long-Term Deferred Tax Assets	0.2	0.2	0.18	0.17	0.17	0.28
Long-Term Deferred Charges	45.09	46.26	48.62	50.97	52.6	52.6
Other Long-Term Assets	6.08	0.91	0.64	0.94	0.58	0.29
Total Assets	140.92	82.05	91.78	101.88	96.97	88.93
Accounts Payable	8.34	9.3	8.54	9.61	10.29	6.92
Accrued Expenses	-	1.87	2.92	3.72	2.11	1.72
Current Portion of Long-Term Debt	3.24	6.4	3.09	1.61	0.05	0.55
Current Portion of Leases	0.69	0.86	0.88	0.76	0.59	0.31
Current Income Taxes Payable	2.22	0.02	0.02	0.01	0	0.02
Current Unearned Revenue	2.89	0.35	0.81	1.05	1.09	4.81
Other Current Liabilities	0.01	0.01	0	0	0	0
Total Current Liabilities	17.39	18.8	16.27	16.76	14.13	14.33
Long-Term Debt	37.15	35.51	37.23	30.8	16.55	9.21
Long-Term Leases	2.81	3.03	3.59	3.97	2.32	1.41
Long-Term Deferred Tax Liabilities	1.66	1.31	1.51	1.75	2.08	5.07
Other Long-Term Liabilities	0	-	0.09	0.29	-	-
Total Liabilities	59.47	59.08	59.12	53.99	35.61	30.4
Common Stock	4.37	4.33	3.71	3.71	3.6	3
Additional Paid-In Capital	76.82	76.64	65.61	65.61	65.45	48.5
Retained Earnings	57.18	-23	-17.76	-16.85	-16.56	-4.65
Treasury Stock	-0.39	-0.41	-0.55	-0.16	-0.09	-0.15
Comprehensive Income & Other	-56.52	-34.59	-18.35	-4.41	8.97	11.84
Shareholders' Equity	81.45	22.98	32.66	47.89	61.36	58.54
Total Liabilities & Equity	140.92	82.05	91.78	101.88	96.97	88.93
Total Debt	43.89	45.8	44.79	37.13	19.51	11.48
Net Cash (Debt)	31.86	-27.13	-19.17	-3.55	9.85	14.36
Net Cash Growth	-	-	-	-	-31.38%	80.10%
Net Cash Per Share	1.39	-1.39	-1.03	-0.20	0.63	0.96
Filing Date Shares Outstanding	21.76	21.59	18.45	18.49	17.96	15.11
Total Common Shares Outstanding	21.76	21.59	18.46	18.49	17.95	14.97
Working Capital	68.4	11.68	20.93	27.45	25.7	18.73
Book Value Per Share	3.74	1.06	1.77	2.59	3.42	3.91
Tangible Book Value	81.32	22.84	32.49	47.74	61.36	58.54
Tangible Book Value Per Share	3.74	1.06	1.76	2.58	3.42	3.91
Buildings	-	0.32	0.31	0.36	0.33	0.28
Machinery	-	1.67	1.71	1.55	1.3	1.13

Source: S&P Capital IQ. Standard template. Financial Sources.